GoldenbergLaw Partner Laura Pittner Named to Farxiga PSC
GoldenbergLaw is pleased to announce the appointment of partner Laura Pittner to the Plaintiff Steering Committee (PSC) tasked with leading the Farxiga Multidistrict Litigation (MDL).
The drugs involved in the litigation, Farxiga and its sister drug, Xigduo XR, are type II diabetes medications used to lower patients’ blood glucose levels. Farxiga and Xigudo XR have been linked to causing ketoacidosis. Ketoacidosis is a life-threatening condition resulting when insulin levels are low and not enough glucose reaches the body’s cells. Symptoms of ketoacidosis include dehydration, excessive urination, severe fatigue, vomiting, abdominal pain, difficulty breathing, and altered mental condition.
In 2015, the FDA required the makers of Farxiga and Xigudo XR to change the drug warning labels to indicate an increased risk of ketoacidosis.
About Laura Pittner
Laura is a partner at GoldenbergLaw and has been with the firm since 2010. She has extensive experience with mass tort and product liability cases. During her time at GoldenbergLaw, she has recovered millions of dollars for recipients of defective metal-on-metal hip replacements, patients poisoned by contaminated steroids, and others severely injured by defective drugs and devices. She currently works on the discovery committee in the Benicar litigation where she has assisted in drafting briefs, reviewing discovery productions, and taking depositions. Her appointment to the Farxiga PSC is only further evidence of her knowledge of mass tort and product liability cases.
Farxiga is a Sodium Glucose Cotransporter 2 (SGTL2) inhibitor, a type of drug used to reduce blood glucose levels in patients with type II diabetes. Farxiga is manufactured by Bristol-Myers Squibb Co., AstraZeneca Pharmaceuticals LP, AstraZeneca PLC, and AstraZeneca AB and was released in 2014.
SGLT2 inhibitors block the pathways used by glucose to enter the bloodstream, lowering the patient’s blood sugar. However, when SGLT2 inhibitors are too effective in blocking the glucose pathways, the reduction in glucose can cause ketoacidosis and kidney injury. Other SGLT2 inhibitors include Invokana and Jardiance. These products have been linked to causing ketoacidosis as well.
Dangers Regarding Farxiga and Xigduo XR
An injury associated with Farxiga is ketoacidosis. SGLT2 inhibitors, like Farxiga and Invokana block pathways the body typically uses to metabolize glucose, causing glucose to be excreted through urination. This causes the body to stop breaking down glucose for use as energy. When there is not enough glucose for the body to metabolize, it breaks down fat instead. Breaking down fat releases acid into the blood leading to dangerously high levels of blood acids or ketones. This occurrence is known as ketoacidosis.
The FDA has released safety communications regarding Farxiga, including reporting on 73 adverse events between 2013 and 2015. The first communication warned about the symptoms and dangers of ketoacidosis and was accompanied by a label change requirement. In a second safety announcement, the FDA required a stronger safety warning regarding kidney injury on Farxiga and Xigduo XR labels.
Farxiga Multidistrict Litigation
The eighteen cases currently involved in the litigation have been consolidated under Multidistrict Litigation (MDL) No. 2776, In Re: Farxiga (Dapagliflozin) Products Liability Litigation. The MDL was formed in the Southern District of New York and assigned to the Honorable Judge Lorna G. Schofield.
GoldenbergLaw is currently accepting Farxiga cases. If you took Farxiga and have been diagnosed with ketoacidosis you may be entitled to compensation. Please call us toll-free at 612-436-5026 for a free consultation.